dronabinol oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 67 Diseases   36 Trials   36 Trials   1248 News 


«12...234567891011121314»
  • ||||||||||  dronabinol oral / generics
    Journal:  Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations. (Pubmed Central) -  Sep 25, 2019   
    Human data examining the sex- and gender-related differences in the effects of cannabinoids and factors underlying these differences are very limited. This represents a critical gap in the literature and needs to be systematically examined in future studies.
  • ||||||||||  ondansetron / generics, fluoxetine / generics, dronabinol oral / generics
    Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis (TP-13) -  Aug 26, 2019 - Abstract #ERS2019ERS_4395;    
    There is currently insufficient evidence to recommend any pharmacotherapy for OSA and no phase-III trials are available. Future studies are advised to account for the underlying mechanisms of the intervention, as current evidence suggests that pharmacotherapy may not be a stand-alone therapy in OSA.
  • ||||||||||  dronabinol oral / generics
    Journal:  Transfer of Inhaled Cannabis Into Human Breast Milk. (Pubmed Central) -  Aug 23, 2019   
    The long-term neurobehavioral effect of exposure to delta-9-tetrahydrocannabinol on the developing brain is unclear. Mothers should be cautious using cannabis during pregnancy and breastfeeding.
  • ||||||||||  dronabinol/palmitoylethanolamide (SCI-110) / SciSparc
    Trial completion, Phase classification:  Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome (clinicaltrials.gov) -  Aug 22, 2019   
    P1,  N=17, Completed, 
    Mothers should be cautious using cannabis during pregnancy and breastfeeding. Recruiting --> Completed | Phase classification: P3 --> P1
  • ||||||||||  dronabinol oral / Generic mfg.
    Trial completion date, Trial primary completion date:  Effects of THC and Alcohol on Driving Performance (clinicaltrials.gov) -  Aug 19, 2019   
    P4,  N=135, Not yet recruiting, 
    Conclusions It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol. Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  dronabinol oral / generics
    Clinical, Journal:  Atrioventricular Nodal Reentrant Tachycardia Triggered by Marijuana Use: A Case Report and Review of the Literature. (Pubmed Central) -  Aug 10, 2019   
    ...Delta-9-tetrahydrocannabinol (THC) is the psychotropic component of marijuana, acting via CB1 and CB2 G-protein coupled cannabinoid receptors...While parasympathetic stimulation can increase the refractory period of the fast conduction pathway, it has no effect on the slow and retrograde pathways, therefore its use creates an ideal milieu for AVNRT initiation and maintenance. Our case report highlights the importance of including marijuana use in the differential diagnosis, as a possible trigger, for patients presenting with AVNRT that is otherwise unexplainable.
  • ||||||||||  dronabinol oral / generics
    Prevalence of Cannabinoid Use in Patients With Gastrointestinal Symptoms (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_2622;    
    Forty-nine (82%) respondents were female, and median age was 43-years-old. Twenty-nine (48%) subjects reported use of cannabinoids within the past year; the most common substances were marijuana (90%) or marijuana and cannabidiol (48%).
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Acute emergencies in oncology (Pubmed Central) -  Aug 3, 2019   
    In addition to stage-adapted pain therapy, supportive measures such as nutritional supplementation, the use of dronabinol in cases of loss of appetite, and antipruritic therapies are outlined. This article provides a succinct summary of the most frequently observed dermato-oncological emergencies with references to the respective detailed literature of associated medical societies and guidelines.
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Medical Use of Cannabinoids. (Pubmed Central) -  Aug 1, 2019   
    In addition, some cannabinoid-based medications have already been approved in various countries, including nabilone and dronabinol capsules for the treatment of nausea and vomiting associated with chemotherapy, dronabinol capsules for anorexia, an oral solution of dronabinol for both vomiting associated with chemotherapy and anorexia, a Δ-tetrahydrocannabinol/cannabidiol oromucosal spray for pain related to cancer and for spasticity and pain associated with multiple sclerosis, and an oral solution of cannabidiol for Dravet and Lennox-Gastaut syndromes. Here, we review the available efficacy, safety and tolerability data for cannabinoids in a range of medical conditions.
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Future Aspects for Cannabinoids in Breast Cancer Therapy. (Pubmed Central) -  Jul 31, 2019   
    Furthermore, selective estrogen receptor modulators (SERMs), including tamoxifen, bind to CB-Rs; this process may contribute to the growth inhibitory effect of SERMs in cancer cells lacking the estrogen receptor. In summary, CBs are already administered to breast cancer patients at advanced stages of the disease, but they might also be effective at earlier stages to decelerate tumor progression.
  • ||||||||||  dronabinol oral / Generic mfg.
    Enrollment open:  Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease (clinicaltrials.gov) -  Jul 28, 2019   
    P1,  N=30, Recruiting, 
    In summary, CBs are already administered to breast cancer patients at advanced stages of the disease, but they might also be effective at earlier stages to decelerate tumor progression. Not yet recruiting --> Recruiting
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Progress in Brain Cannabinoid CB Receptor Research: From Genes to Behavior. (Pubmed Central) -  Jul 13, 2019   
    These new findings regarding brain versus spleen CB2R isoforms may in part explain why early studies failed to detect brain CB2R gene expression. Here, we review evidence supporting the expression and function of brain CB2R from gene and receptor levels to cellular functioning, neural circuitry, and animal behavior.
  • ||||||||||  dronabinol oral / generics
    Clinical, Journal:  Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes. (Pubmed Central) -  Jul 12, 2019   
    Regarding Cannabis oil, a new procedure has been developed that allows significantly higher recovery rates for THC and CBD compared with those for water-based extraction methods (decoction) and those for oil-based methods currently in use. Moreover, based on the results, it is possible to affirm that the prescription of Cannabis-based decoctions should not be the recommended first-choice solution for therapy, considering the low concentration of THC and CBD and, consequently, the high volume of decoction that the patient would have to ingest.
  • ||||||||||  dronabinol oral / generics
    Retrospective data, Review, Journal:  Systematic review and meta-analysis of cannabinoids in palliative medicine. (Pubmed Central) -  Jul 11, 2019   
    In another study comparing megestrol to dronabinol in HIV patients, megestrol treatment led to higher weight gain without any differences in tolerability and safety. We found no convincing, unbiased, high quality evidence suggesting that cannabinoids are of value for anorexia or cachexia in cancer or HIV patients.
  • ||||||||||  dronabinol / generics
    Journal:  Cannabinoids for the treatment of chronic refractory pruritus. (Pubmed Central) -  Jul 3, 2019   
    We found no convincing, unbiased, high quality evidence suggesting that cannabinoids are of value for anorexia or cachexia in cancer or HIV patients. No abstract available
  • ||||||||||  dronabinol oral / Generic mfg.
    Trial completion:  Cannabinoids for Pain Control During Medical Abortion (clinicaltrials.gov) -  Jun 24, 2019   
    P4,  N=72, Completed, 
    Development of guidelines regarding cannabis potency is critical for reducing the costs associated with negative health outcomes. Active, not recruiting --> Completed
  • ||||||||||  dronabinol / generics
    Journal:  A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. (Pubmed Central) -  Jun 22, 2019   
    ...The roles of oral and intrathecal baclofen and of delta-9-tetrahydrocannabinol/cannabidiol (THC:CBD) oromucosal spray in treating MS spasticity-related gait impairment are reviewed...Oral baclofen and tizanidine are generally used for first-line treatment of MS spasticity but are ineffective in approximately 40% of cases...In studies of patients with resistant MS spasticity, THC:CBD spray consistently improved the timed 10-meter walk test and significantly improved multiple spatial-temporal and kinematic gait parameters. THC:CBD oromucosal spray warrants further investigation as a treatment for MS spasticity-related gait impairment.
  • ||||||||||  dronabinol oral / Generic mfg.
    Phase classification:  Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease (clinicaltrials.gov) -  Jun 21, 2019   
    P1,  N=30, Not yet recruiting, 
    THC:CBD oromucosal spray warrants further investigation as a treatment for MS spasticity-related gait impairment. Phase classification: P2 --> P1
  • ||||||||||  dronabinol / generics
    Journal:  Alcohol and marijuana use among young injured drivers in Arizona, 2008-2014. (Pubmed Central) -  Jun 5, 2019   
    Broader enforcement of existing laws targeting underage access to alcohol and alcohol-impaired driving could further reduce injuries among young Arizona drivers. To further reduce crash-related injuries and fatalities among all road users, the state could consider implementing a primary enforcement seat belt law and a universal motorcycle helmet law.
  • ||||||||||  dronabinol / generics
    Journal:  A Brief Background on Cannabis: From Plant to Medical Indications. (Pubmed Central) -  May 26, 2019   
    ...The two most prevalent and commonly known cannabinoids in the cannabis plant are delta-9-tetrahydrocannabinol (THC) and cannabidiol...Side effects of cannabis include psychosis and anxiety, which can be severe. Here, we provided a summary of the history of cannabis, its pharmacology, and its medical uses.
  • ||||||||||  dronabinol oral / Generic mfg.
    Enrollment closed:  Cannabinoids for Pain Control During Medical Abortion (clinicaltrials.gov) -  May 22, 2019   
    P4,  N=72, Active, not recruiting, 
    Here, we provided a summary of the history of cannabis, its pharmacology, and its medical uses. Recruiting --> Active, not recruiting
  • ||||||||||  dronabinol / generics
    PK/PD data, Journal:  Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. (Pubmed Central) -  May 11, 2019   
    ...Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design...Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group. A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.
  • ||||||||||  dronabinol oral / Generic mfg.
    Trial primary completion date:  Cannabinoids for Pain Control During Medical Abortion (clinicaltrials.gov) -  May 7, 2019   
    P4,  N=62, Recruiting, 
    These findings suggest that further investigation into the role of cannabinoid medications for non-opioid pain control in the post-arthroplasty patient may hold merit. Trial primary completion date: Mar 2019 --> Jun 2019
  • ||||||||||  dronabinol oral / Generic mfg.
    Enrollment closed, Trial primary completion date:  Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder (clinicaltrials.gov) -  Apr 25, 2019   
    P=N/A,  N=130, Active, not recruiting, 
    Previous modest cannabis use blunts the acute behavioral and neurophysiological effects of ∆9-THC, which are more marked in people who have never used cannabis. Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2019 --> Dec 2019